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ABSTRACT 
 
 
Pseudogenes have been defined as non-functional sequences of genomic DNA 
originally derived from functional genes. Over the past decade pseudogenes have been 
suitably investigated and often exhibit functional roles, such as gene expression, gene 
regulation, and generation of genetic (antibody, antigenic, and other) diversity. In 
particular, recent studies showed that pseudogene can also act as microRNA-decoying 
competitive endogenous RNA and when deregulated can promote oncogenesis.  
In this study, I investigated the role of B-RAFps as microRNA-decoying 
competitive endogenous RNA that is able to regulate BRAF expression and MAPK 
pathway activation. Furthermore, I participated in demonstrating that mice engineered 
to overexpress either the full-length B-Rafps or only its “CDS” or “3’ UTR” develop 
aggressive diffuse large B-cell lymphoma. I demonstrated in vitro that this effect is 
due to the microRNA-decoying competitive endogenous RNA potential of B-RAFps 
toward its coding gene BRAF. In this way B-RAFps is able to regulate BRAF 
expression and MAPK activation. These results were submitted for publication in an 
article by Karreth et al. (103) “The BRAF Pseudogene is a competitive endogenous 
RNA”. 
In addition to the study of BRAFps I started to investigate the role of the 
CD46P1 pseudogene as ceRNA. Preliminary data show that CD46P1 is expressed in 
some prostate cancer and lymphoma cell lines. In particular, it seems expressed in 
cancer cell lines established from primary tumours and not from metastasis. It could be 
possible that the primary tumour microenvironment could influence the transcription 
activation of genes in the RCA cluster where CD46P1 and CD46 are located. 
 14 
 
 These preliminary data on CD46P1 might help to design and execute 
experiments that will elucidate the reasons for differential CD46P1 expression in 
cancer cell lines and its possible role as ceRNA. 
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INTRODUCTION 
 
1.1 The competing endogenous RNA world 
 
1.1.1 The dark matter of the genome: non-coding RNA (ncRNA) 
 
In the past few years, thanks to new technologies such as the whole-genome 
and whole-transcriptome sequencing, it has become even more clear that only a small 
proportion of the mammalian genome (i.e. human, mouse), is transcribed into mRNAs 
which is subsequently translated into protein. In fact, less than 2% of our genome 
encodes protein-coding transcripts, even though over three quarters of the genome is 
transcribed into what was previously regarded as “dark matter”- non-coding RNA 
transcripts (ncRNAs) (1). 
It is increasingly evident that ncRNAs can and do have a very wide repertoire 
of biological functions in cellular physiology, development, metabolism, and that they 
are widely employed as a means of gene regulation especially in higher eukaryotes (2). 
The ncRNAs are a heterogeneous class of RNAs which are divided into two 
major categories on the basis of their average sizes: the small non-coding RNAs 
(sncRNAs) with a length less than 200 base pairs (bp) and the long non-coding RNAs 
(lncRNAs) with a length within a range of 200 bp to ~100 kilobases (kb).  
The small ncRNAs include many different RNAs that are highly conserved in 
evolution and have their own peculiar functions. Some well-studied sncRNAs are: 
microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI interacting RNAs 
(piRNAs), transfer RNA (tRNA), small nuclear RNA (snRNA) and small nucleolar 
RNA (snoRNA) (3).  
The lncRNAs, instead, are poorly conserved among different species when 
compared to sncRNAs. They are usually low expressed making them look like 
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transcriptional noise. Despite this, a lot of evidence has accumulated showing that 
lncRNAs play a significant role in a wide variety of important biological processes (4, 
5), including transcription, splicing, translation, protein localization, regulation of 
nuclear import (Nron1) (6), cellular structure integrity, imprinting (H19) (7), cell 
cycle, apoptosis and X-chromosome inactivation (Xist) (8). In addition to this, it has 
been suggested that lncRNAs may regulate cancer progression (9) and development of 
many other human diseases (10). 
The lnRNAs are sub-classified according to their genome localization (11). 
The large intergenic non-coding RNAs (lincRNAs) are distinct transcript units 
located in sequence space that do not overlap protein-coding gene. They have an 
average length of 1Kb, they are mainly transcribed by RNA Pol II from both strands, 
they are spliced and polyadenylated (12). A second group is made by pseudogenes 
which are considered “relics” of genes that have lost their coding potential due to 
mutation in their sequence. They can be actively transcribed but not translated into 
proteins (see paragraph). A third group of lncRNAs is the long intronic ncRNAs. 
They are encoded within the introns of protein-coding genes and for a long time they 
were recognized only as precursors of shorter RNAs (miRNA, snoRNAs etc.) (13). 
Recent evidences suggest that they have differential expression patterns, respond to 
stimuli, and can be misregulated in cancer (14). A final class of lncRNAs are the 
sense and antisense lncRNAs. The sense lncRNAs are transcribed from the sense 
strand of protein-coding genes, containing exons from protein-coding genes. They 
may overlap with part of protein-coding genes, or cover the entire sequence of a 
protein-coding gene. Antisense lncRNAs, instead, are transcribed from the antisense 
strand of protein-coding genes, overlapping with exonic or intronic regions or 
covering the entire protein-coding sequence through an intron (15). 
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 1.1.2 Pseudogenes  
 
Pseudogenes are sequences in the genome that have close similarities to one or 
more paralogous functional genes, but in general are unable to be transcribed (16). The 
non-functionality of the pseudogenes is often caused by the lack of functional 
promoters or other regulatory elements. As a result, these sequences are released from 
selection pressure and are free to accumulate non-gene-like features such as frame 
disruptions (frameshifts, in-frame stop codons, or disrupting interspersed repeats) in 
the original protein-coding sequence (CDS) (17). Currently, approximately twenty 
thousand pseudogenes are estimated which is comparable to the number of protein-
coding genes in human (18). 
On the basis of origin and characteristic features, the pseudogenes can be 
categorized as unitary pseudogenes, processed or retrotransposed pseudogenes and 
duplicated or non-processed pseudogenes.  
Unitary pseudogenes are like genetic “relics” of genes whose functions were 
important in ancestral species but became unnecessary in modern species. These 
pseudogenes are a natural consequence of mutations that failed to be eliminated by 
negative natural selection, because the functions of their products become unnecessary 
in present species (Figure 1). 
 
 
Figure 1: Unitary pseudogene graphical representation. 
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More than 70 different unitary pseudogenes have been identified in the human genome 
in the last years (19). A classic example of a unitary pseudogene is the gene that coded 
for the enzyme L-gulono-γ-lactone oxidase (GULO) in primates. In all mammals 
studied besides primates, GULO catalyses the terminal step of L-ascorbic acid 
biosynthesis: in human and other primates it exists only as a unitary pseudogene 
(GULOP) (20). 
The second class of pseudogenes is the processed or retrotransposed 
pseudogenes. They originate through germline retroposition, where the processed 
transcript of a functional gene is reverse transcribed and incorporated into a staggered 
chromosome break, followed by DNA synthesis and repair (21) (Figure 2). Once these 
pseudogenes are inserted back into the genome, they usually contain a poly-A tail and 
lack introns and 5’ promoter sequence (22). 
 
                       Figure 2: Processed pseudogene graphical representation. 
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Processed pseudogenes expression is usually regulated by promoter and 
enhancer elements that differ from their parental genes. Several studies suggest that the 
enzymatic machinery that guides the process of reverse transcription and insertion of 
cDNA sequences are LINE1 non-LTR retrotransposons (23).  
The third pseudogene category is the duplicated or non-processed pseudogenes. 
They usually originate from a gene duplication mechanism producing an extra copy of 
the gene which, being unnecessary, can accumulate mutations without damaging the 
organism, but they can also be generated by unequal crossing-over mechanisms (24) 
(Figure 3). Duplicated pseudogenes usually have all the same characteristics of genes, 
including an intact exon-intron structure and promoter sequences. They are often 
located next to their paralogous parent gene in clusters of similar functional sequences 
and even can be inserted into a different chromosome. Depending on the order in 
which mutations accumulate over evolutionary time, a duplicated pseudogene may still 
be transcribed and, even if rarely, could become a functional unit acquiring a novel 
function or mode of expression and become fixed within a population (25). 
 
 
 
Figure 3: Duplicated pseudogene graphical representation. 
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1.1.3 MicroRNAs 
 
MicroRNAs (miRNAs) comprise a large family of ~21-nucleotide-long 
ncRNAs that are highly conserved in the genome of viruses, plants, animals, and 
humans. Biogenesis of miRNAs takes place through a multi-step process that starts 
into the nucleous where the RNA polymerase II transcribes a hairpin loop of RNA 
(pri-miRNA) (26). The pri-miRNA is several kilobases long, polyadenylated at its 3′ 
end and capped with a 7-methylguanosine cap at its 5′ end. After the pri-miRNA 
transcript has been generated in the nucleus, it is cleaved into a precursor-miRNAs 
(pre-miRNAs) by Drosha, a RNA polymerase III. The pre-miRNA is then exported 
through the nuclear membrane protein exportin 5 into the cytosol (27). In the cytosol, 
the RNA polymerase III Dicer processes the pre-miRNAs into a ~20-bp 
miRNA/miRNA duplex containing a mature miRNA strand (leading strand) and its 
opposite complementary miRNA strand.  
Only the leading strand is incorporated into the RNA-induced silencing 
complex (RISC), which directs the regulation of mRNA by recognizing the miRNA-
response elements (MRE) (Figure 4). MREs are localized on the 3′ untranslated region 
(UTR), coding sequence (CDS), and the 5′ UTR of protein coding RNA, and, in 
addition, can also be found on non–protein coding transcripts such as long noncoding 
RNAs (28,29). The result of the binding of the miRNAs-RISC complex to a specific 
mRNAs usually results in the repression of target gene expression by either inhibiting 
translation or destabilizing the mRNA (30). 
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                           Figure 4: Maturation process of miRNAs.  
 
The importance of miRNAs in normal cellular development and metabolism is now 
being realized. MiRNAs are involved in regulating many processes such as 
proliferation, differentiation, apoptosis and development (31, 32). Deficiencies or 
excesses have been correlated with a number of clinically important diseases ranging 
from myocardial infarction to cancers (33).  
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1.1.4 The ceRNA network (ceRNET) 
 
The competing endogenous RNA (ceRNA) hypothesis stems from the 
observation that RNA transcripts often share same microRNA response elements 
(MREs) for multiple distinct microRNAs and conversely, individual microRNAs often 
target at the same time multiple distinct transcripts (34). This target multiplicity has led 
to the hypothesis that different RNA transcripts, both protein-coding and non-coding, 
have the ability to compete for microRNA binding and co-regulate each other in 
complex ceRNA networks (ceRNETs) (35). In this “cross talk” MREs can be 
considered as the building blocks of a new language, the “RNA language”. 
Importantly, knowing the MRE overlap between multiple RNAs allows bioinformatic 
prediction of the interaction between RNAs, which are not yet correlated to each other 
(36).  
In a recent paper, Ala et al. (37) define a precise set of rules to explain the 
“communication” within the ceRNA networks. Firstly they show that the optimal 
ceRNA-mediated cross-regulation occurs at a near equimolar equilibrium of all 
ceRNAs and miRNAs within a network (Figure 5-A). Secondly, they state that the 
relative abundance of miRNA and ceRNAs influences the cross-talk as does the 
number of shared MREs. In fact, the ceRNA cross-interaction increases with the 
numbers of shared miRNA and it is weakened when a ceRNA pair is targeted by too 
many non-shared miRNAs (38) (Figure 5-B). Thirdly the cross-talk is not limited to 
two transcripts which share MREs but can be amplified by the interaction with a third 
transcript (Figure 5-C).  
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Figure 5: Competitive endogenous RNA network suggested dynamics.  
 
Changes in this cross-talk equilibrium may promote diseases like cancers. 
Misregulation of miRNAs, in fact, appears to play a fundamental role in the 
occurrence, growth and dissemination of many cancers (39).  
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1.1.5 Pseudogenes as ceRNAs 
 
In 2010, the group of Pier Paolo Pandolfi hypothesized and demonstrated 
experimentally that pseudogenes, due to their high-sequence homology with their 
ancestor genes, can act as legitimate bona fide microRNA competitors (ceRNAs), 
thereby actively competing with their ancestral protein-coding genes for the same pool 
of microRNAs through sets of conserved MREs (35). These findings were particularly 
relevant because they attributed a new function to transcribed pseudogenes, which 
have been considered to be biologically useless owing to their inability to be translated 
into functional proteins. In particular, they showed this by studying the role of the 
PTEN pseudogene (PTENP1) as competing endogenous RNA for its protein-coding 
gene PTEN. PTEN is a haploinsufficient tumor suppressor that is commonly mutated 
or lost in tumours (35, 40). The 3’ UTR regions of either the PTENP1 pseudogene and 
PTEN gene are highly homologous and contains numerous seed matches for miRNAs 
that were previously validated to repress PTEN expression. Overexpression and RNA 
interference silencing experiments confirmed that PTENP1 regulates PTEN thanks to 
the shared MREs (35, 40, 41).  
A similar relationship was also observed between the pseudogene KRAS1P and 
its parental oncogene KRAS (35).  
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1.2 B-RAF 
 
1.2.1 Gene and protein  
 
The v-raf murine sarcoma viral oncogene homolog B (B-RAF) is located on the 
long (q) arm of chromosome 7 at position 34. The B-RAF gene is composed of 18 
exons spanning a region of almost 200 kb (42) (Figure 6). The gene is transcribes into 
a transcript of 2478 bp, which is translated into a protein of 94-kDa. 
 
 
Figure 6: Human B-Raf gene graphic structure. 
 
B-RAF protein belongs to a family of serine-threonine protein kinases that 
includes A-RAF and C-RAF (Raf1).  The three kinases have homology in their 
structure, in particular they share three conserved regions (CR): CR1, CR2, and CR3. 
CR1 is composed of a RAS-binding domain (RBD) and a cysteine-rich domain 
(CRD), which can bind two zinc ions. It is located near the N-terminus of the protein 
and it allows the interaction of RAF proteins with RAS. CR2 is a serine/threonine rich 
domain that contains a serine which when phosphorylated can bind to 14-3-3, an 
inhibitory regulatory protein. Finally, the CR3 region, located near the C-terminus, is 
the catalytic domain of the protein (43, 44) (Figure 7).  
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Figure 7: Graphical comparison of Raf proteins structure. 
  
 
. 
 1.3.2 B-RAF function: the RAF–MEK–ERK MAPK cascade 
 
B-RAF is a serine/threonine kinase that belongs to the 
RAS/RAF/MEK/ERK/MAPK pathway, which is involved in the transduction of 
mitogenic signals from the cell membrane to the nucleus (45). Binding of extracellular 
ligands such as growth factors, cytokines and hormones to their cell-surface receptors 
activates RAS-GTP protein, which resides at the inner side of the cell membrane.  
When RAS proteins are activated, RAF proteins are able to recognize the 
phosphorylated sites and bind them with their RAS binding domain (RBD) in the CR1 
region (46). The activation of RAF proteins lead to activation of the dual-specificity 
protein kinases MEK1 and MEK2 (mitogen-activated protein kinase -MAPK) through 
phosphorylation of two serine residues at positions 217 and 221 found in the activation 
loop (47). While RAF isoforms are enzymes of relatively low abundance, the high 
concentration of MEKs allows for amplification of signaling. The downstream targets 
of MEK proteins are the extracellular signal-regulated proteins ERK1 and ERK2. 
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Activated ERKs regulate growth factor-responsive targets in the cytosol and also 
translocate to the nucleus where they phosphorylate a number of transcription factors 
regulating gene expression. More of 160 proteins are described as downstream targets 
of the RAS/RAF/MEK/ERK/MAPK pathway (48). 
      
 
Figure 8: RAS/RAF/MEK/ERK/MAPK pathway 
 
Depending on the cellular context, this pathway mediates diverse biological 
functions such as cell growth, survival and differentiation predominantly through the 
regulation of transcription, metabolism and cytoskeletal rearrangements (43, 49).  
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Alteration of one or more effectors of this pathway can deeply influence the 
cells fate. In fact, the RAS/RAF/MEK/ERK/MAPK pathway is one of the most 
frequently deregulated signal transduction pathways in human cancers, often through 
gain-of-function mutations of RAS and RAF family members (50). 
 Some examples of genes activated by RAS/RAF/MEK/ERK/MAPK pathway 
that can promote cell transformation and metastasis are: cyclin D1, cyclin D2 and 
cyclin D3 (self-sufficiency in growth), VEGF (angiogenesis), c-myc (insensitivity to 
antigrowth signals), b3-integrin (tissue invasion and metastasis) and mdm2 (apoptosis 
evasion, limitless replicative potential and angiogenesis) (51).  
 
 
 
 
1.2.3 B-RAF in cancer 
 
B-RAF protein was the second RAF protein isoform to be identified and in 
contrast to the ubiquitous C-RAF expression was initially considered to be mainly a 
brain specific isoform (52). For this reason the attention was focused for a long time on 
the study of the C-RAF isoform. This focus shifted however to some degree with the 
identification of B-RAF as a mutational target in various human cancers. In fact, in 
June 2002, Davies H. and colleagues (53) performed a sequencing screen of 923 
cancer samples and identified missense mutations of the B-RAF gene in approximately 
70% of human malignant melanomas (54). Gradually, other studies revealed the B-
RAF involvement in 50% of thyroid cancers (55) 15% of colorectal cancers (56, 57) 
and 35% of ovarian carcinomas (58).  
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   Mutations were also detected at a low frequency in gliomas, lung, sarcomas, 
breast and liver cancers (59) (Figure 9). 
 
              
                   Figure 9: Frequency B-RAF mutations in human cancers. 
 
 Most of the B-RAF mutations were identified within the kinase domain. The 
most frequent mutation, about 90% of all B-RAF mutations found in cancer, is a single 
amino acid substitution, a valine (V) being substituted for by glutamate (E) at codon 
600 (V600E) (60). B-RAF V600E exhibits a 500-fold increase in kinase activity, 
constitutively stimulating the activation of MEK/ERK signalling in the absence of 
extracellular stimuli (61). Recently, Tiacci et al. using massively parallel sequencing 
observed that the V600E mutation is present in 100% of cases of hairy cell leukaemia 
(62).  
Interestingly, a corresponding mutation to B-RAFV600E was not detected in C-
RAF or A-RAF in human cancers. This is most likely due to the fact that C-RAF and 
A-RAF hold a tighter regulation of their kinase domain than B-RAF, thus, a single 
mutation is insufficient for substantial kinase activation (63). 
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Mutations in B-RAF commonly occur in the same cancer types that harbour 
RAS mutations in a mutually exclusive pattern with RAS mutations (< 1%), 
suggesting that these genetic alterations activate common downstream effectors of 
transformation (69). 
 
 
 
 
 
 
1.2.4 B-RAF pseudogene  
 
Two human B-RAF loci (B-RAF-1 and B-RAF-2) have been identified in 
human genome. B-Raf-1 is located on chromosome 7q34 and encodes a functional B-
Raf protein. B-RAF-2, instead, is located on chromosome Xq13 and has been predicted 
to be B-RAF-1 inactive unprocessed pseudogene (BRAFP1) (42). The homology 
between the two transcripts is over 90%. The pseudogene contains 2 non-coding exons 
and one intron and it is transcribed in a transcript of 2,703 bps (65). 
 In mice, B-RAF protein coding gene is located on chromosome 6 and is 
transcribed into two different transcripts, which give rise to two B-RAF isoform 
respectively of 804 AA and 750 AA. Also in mouse genome it has been identified a B-
RAF pseudogene locus located on chromosome 10. It also shares a very high 
homology with its corresponding coding gene (66). 
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1.2.5 B-Raf gene and pseudogene homology in mice and human 
 
When analyzing the sequence of the B-RAF gene and its pseudogene and 
comparing those in either mice or human the sequence homology is > 90%. Karreth et 
al. in the paper under revision “The BRAF pseudogene is a proto-oncogenic 
competitive endogenous RNA” (103) shows that human B-RAF gene and pseudogene 
share 40 different miRNA response elements (MREs) while mouse B-RAF gene and 
pseudogene around 52 (Figure 10).  
 
 
         
             Figure 10: Total comparing MREs in B-RAF and B-RAFps. 
 
The high number of MREs shared allows the transcripts to cross talk to each 
other following the ceRNA theory. 
 
 
 
 
 
 
 
 32 
 
1.2.6 TRE-B-Rafps mice develop diffuse large B-cell lymphoma  
 
Karreth et al. (103) report that mice engineered to overexpress either the full-
length B-Rafps or only its “CDS” or “3’ UTR” developed aggressive diffuse large B-
cell lymphoma. Lymphoma nodules were commonly observed in the kidneys, livers 
and lungs and histological analysis revealed microscopic organ infiltration (Figure 11) 
 
Figure 11: H&E staining of kidney and lung. 
 
In addition to these, all the TRE-B-Rafps mice showed splenomegaly and mild 
lymphadenopathy (Figure 12). 
 
Figure 12: Weight of spleen from control and B-Rafps mice. 
.  
We demonstrated for the first time the oncogenic potential of a pseudogene in 
an engineered mouse model and indicate that ceRNA-mediated regulation is an 
important mechanism of gene expression in vivo.  
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1.3 The Membrane Cofactor Protein: CD46 
 
 
1.3.1 CD46: gene and protein 
 
The Membrane Cofactor Protein (MCP)-CD46 gene is a member of the 
regulators of complement activation (RCA) family gene cluster located on the long (q) 
arm of chromosome 1 at position 32 (67). The RCA gene cluster contains more than 
60 genes of which 15 are complement related genes. These genes code for both 
soluble and transmembrane proteins which play a pivotal role in regulating 
complement activity such as Factor H, the α-chain of the C4b-binding protein 
(C4bpα), the decay accelerating factor (DAF), the complement receptor type 1 (CR1) 
and the complement receptor type 2 (CR2) (68, 69). 
The CD46 gene consists of 14 exons and 13 introns for a total length of ~43 kb 
(Figure 13).  
 
 
Figure 13: Schematic structure of human CD46 gene. 
 
Exon 1 encodes the 5’UTR and signal peptide, exons 2-6 encode four short 
consensus repeat (SCRs), while exons 7, 8 and 9 for an area of high O-glycosylation 
rich in serine, proline and threonines (STP). Exon 10 encodes a 13-amino-acid stretch 
of unknown significance (UK) while exon 11 and 12 encodes for the hydrophobic 
transmembrane domain (TM) and the basic amino acid anchor. Exon 13 is 
 34 
 
alternatively spliced: if it is present a 93-bp stretch codes for the cytoplasmatic 
domains of 16 amino acids (CYT-1), if it is absent the exon 14 encodes for a totally 
different cytoplasmatic tail (CYT-2) of 23 amino acids. Due to the presence of an in-
frame stop codon, the presence of exon 13 converts exon 14 into the 3’UTR. In the 
case exon 13 is spliced out exon 14 encodes for CYT-2 and the 3’UTR region of MCP 
(70). 
 
 
1.3.2 Expression pattern and its regulation 
 
CD46 is expressed on all human nucleated cells except on red blood cells. Four 
are the main isoforms generated by an alternative splicing. These isoforms differ in the 
quantity of juxtamembranous O-glycosylation regions and by expression of a 16 or 23 
amino acid cytoplasmatic tail (CYT-1 or CYT-2) (Figure 14).          
 
                          
Figure 14: Human CD46 isoforms. 
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The relative ratio of the isoforms is inherited in an autosomal co-dominant way 
with three phenotypes in the population: 65% express predominantly the high O-
glycosylated isoform, 6% express the less O-glycosylated and 29% express both forms 
with approximately equal ratio (71).  In addition to this, the CD46 isoforms’ 
expression pattern is tissue-specific: the less O-glycosylated form bearing the CYT-2 
cytosplasmatic tail is mostly expressed in male germ cells and brain while the higher 
O-glycosylated is expressed in kidney, the brain and salivary glands (72). While most 
cells express all four isoforms, some tissues are characterized by a distinct and specific 
CD46 expression pattern: brain, kidney and salivary glands, for instance, only express 
CYT-2-bearing isoforms (73).   
 
 
 
1.3.3.1 Complement 
 
The complement system can be activated via three different pathways: the 
classical pathway (activated by antibodies and immune complexes), the lectin pathway 
(triggered by pathogen-specific lectins) and the alternative pathway (initiated directly 
on microbial surfaces or triggered by properdin binding to targets). CD46 is most 
effective in controlling the ampliﬁcation loop of the alternative pathway (74). In fact, 
CD46 is an intrinsic cofactor for the factor-I-mediated cleavage of C3b and C4b (75). 
The cleavage of C3b produces the fragment C3bi, which is unable to support further 
complement activation. In this way, C3b is not deposited onto cells surfaces and 
cannot induce the formation of the membrane attack complex (MAC) and subsequent 
lysis and/or the uptake of C3b-opsonized pathogens by macrophages and neutrophils. 
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The cleavage of C4b by factor I and CD46 produces the fragments C4c and C4d. C4c 
is liberated into the extracellular milieu whereas C4d, incapable of continuing the 
complement cascade, remains attached to the target (76) (Figure 15). 
 
-  
Figure 15: CD46 protein mechanism of action. 
 
CD46 is not the only membrane-bound protein able to protect host cells from 
complement attack. Other proteins with similar function are CD35 (complement 
receptor type-1 (CR1)), CD55 (decay-accelerating factor (DAF)) and CD59.  They 
differ from each other in their mechanism of action and in the way in which they 
attach to the cells surfaces. In particular, CD35 and CD55 contribute to the control of 
C3 activation while CD59 interferes with the assembly of the MAC at the terminal 
step of the complement activation cascade (77). 
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1.3.3.2 Pathogen interaction 
 
CD46 has been “labeled as a pathogen’s magnet” (78) due to the several 
pathogens for which it is a cell receptor. This includes the Edmonston strain of 
measles virus, human herpesvirus-6 (HHV-6), adenoviruses A and B, type IV pili of 
Neisseria gonorrhoeae and Neisseria meningitidis as well as group A streptococcus 
(79-82).  
Engagement of CD46 by pathogens has implications beyond the simple cell 
adhesion. Pathogens may use CD46 for activation of intracellular signaling cascades 
that give them a foothold in the host, by either facilitating the breach of protective 
host/environmental borders or creating an altered immune microenvironment, or both. 
For example the binding of measles virus (MV) to CD46 decreases IL-12 production 
in human macrophages (83) and alters internalization pathways of CD46 in non-
lymphoid cell lines. In addition the MV attachment induces CD46 turnover resulting 
in enhanced susceptibility of the cell to complement-mediated lysis (84). 
 
 
1.3.3.4 Fertilization 
 
The research of a murine homologue of human CD46 revealed that murine 
CD46 gene is only expressed on spermatozoa (85). This led to investigations into the 
role of CD46 in the human fertilization process. Many studies have revealed that 
CD46 plays a key role in egg-sperm fusion in human and mice (86). In spermatozoa, 
CD46 is located on the inner acrosomal membrane where it is critical in the negative 
regulation of the acrosome reaction, a fusion of the plasma membranes of the sperm 
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and oocyte (87). Lack or severely reduced expression of CD46 on spermatozoa has 
been connected with idiopathic male infertility (88). 
 
 
1.3.4 CD46 role in cancer 
 
Trace of activated complement components (C3, C4) and the terminal MAC 
(C5b-C9) have been found deposited in tumor tissue such as breast (89) and papillary 
thyroid carcinoma (90). In vitro studies of tumor cell lines have demonstrated that 
human tumor cells can activate to some degree human complement but are rather 
resistant to lysis (91). Tumor cell resistance to complement-mediated lysis employs a 
collection of protective strategies and most of them are probably also utilized by 
normal tissues to resist accidental cell damage following local activation of 
complement (92).     
The resistance of tumor cells to complement-mediated cytotoxicity depends on 
basal or induced mechanisms. The basal mechanisms are spontaneously expressed in 
cells without a need for prior activation. An example is the membrane-associated 
complement regulatory proteins (CD46, CD55 and CD59) which are normally 
expressed on normal cells but appear to be over-expressed on tumors cells (93). 
Numerous studies have also shown that the overexpression of these proteins plays an 
important role in cancer immunoresistance. In fact in order to succeed in tumor 
eradication with antibody and complement, novel methods and reagents that overcome 
the protective capacity of mCRPs are needed such as specific inhibition of mCRP 
activity achieved with monoclonal antibodies directed to CD46, CD55 or CD59 (94). 
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Furthermore, tumor cells can also secrete several soluble complement 
inhibitors in the microenvironment, such as C1 inhibitor, factor H and factor H-like 
protein (95) and may also express proteases that degrade complement proteins, such as 
C3.  Besides this basal resistance, nucleated cells resist complement damage by 
removing the membrane attack complexes (MAC) from their surface. Calcium ion 
influx and activation of protein kinase C (PKC) (96) and of mitogen-activated protein 
kinase (MAPK) have been demonstrated to be associated with the complement-
induced enhanced resistance to lysis (97).  
 
 
 1.3.5 The CD46P1 pseudogene 
 
The CD46P1 pseudogene (Gene ID: 4182) was discovered in 1992 when the 
human regulators of complement activation gene cluster (RCA cluster) was partially 
characterized with yeast artificial chromosomes (YACs) (98).  
 It is an unprocessed pseudogene located on the long (q) arm of chromosome 1 
at position 32 very close to its coding- CD46 gene locus (Figure 16).  
The CD46P1 pseudogene has a total length of ~12.18 kb.  
 
 
Figure 16: CD46P1 pseudogene genomic locus. 
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2. Aims of the study 
 
This study has been conducted in Italy at the CEINGE-Biotecnologie Avanzate 
of Naples, and in USA at Harvard Medical School-Beth Israel Deaconesses Medical 
Center in Boston. 
The main aim of this study was to investigate the role of long non-coding 
RNAs (lncRNAs), in particular pseudogenes, as competing endogenous RNAs 
(ceRNAs) in cancer. Thanks to recent discoveries, it has become clear that two 
different transcripts can cross-talk to each other by sharing the same microRNA 
responsive elements (MREs).  
In particular, I focused my attention on the two pseudogenes BRAFps and 
CD46P1. Their deregulation could affect cell physiology and could lead to 
oncogenesis. 
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3. Materials and Methods 
  
3.1 Cell lines 
 
NIH3T3 and HCT116 cells lines were purchased from ATCC, Dicer mutant 
HCT116 cells were provided by B. Vogelstein and Dicerflox/delta and Dicerdelta/delta 
mouse sarcoma cells were provided by P. Sharp (KPCD cell line). The prostate cancer 
cell lines Du-145, PC-3, LNCaP, V-CaP, 22Rv1 were obtained by CEINGE-
Biotecnologie Avanzate cell bank (Naples, Italy).  PC-9 cells were provided L. 
Cantley (Harvard Medical School, Boston, USA) and Ly8 cells were provided by R. 
Chiarle.  NIH3T3, HCT116, Dicer mutant HCT116, Dicerflox/delta and Dicerdelta/delta 
mouse sarcoma cells, E2 B-Raffl/fl LNCaP, DU-145,PC-3, V-CaP cell lines were 
grown in Dulbecco's Modified Eagle Medium (DMEM, Sigma-Aldrich, Oakville, ON) 
supplemented with 10% Fetal Bovine Serum (FBS, Gibco, Carlsbad, CA),  2mM L-
glutammine (Cambrex, East Rutherford, NJ) . PC-9 and Ly8 cells were grown in 
RPMI-1640 containing 10% DMEM and 2mM L-glutamine.  
Cells were regularly tested with MycoAlert (Lonza) to ascertain that cells were 
not infected with mycoplasma and incubated at 37°C in a humidified atmosphere 
containing 5% CO2. The cells were fed fresh growth medium every 2-3 days and at 
confluence they were subcultured using trypsin-EDTA (0.05%, 0.02%). 
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3.2 RNA 
 
 3.2.1 RNA isolation and DNAse treatment 
 
Total RNA was extracted by using TRIzol Reagent (Ambion, USA). 500 μL of 
TRIzol was added to cells pellets (around 3 x 106 cells for sample) and incubated for 5 
minutes at room temperature (Rt). 100 μL of Chloroform was added to each sample, 
shaken vigorously and rested for 3 minutes. After centrifugation at 13,000 rpm for 15 
minutes at 4°C the aqueous phase was transferred in a new Eppendorf tube and mixed 
with an equal amount of isopropanol. The samples were left to rest at Rt temperature 
for 10 minutes and then were centrifuged at 13,000 rpm at 4°C for 10 minutes. The 
RNA pellet was washed once with 250 μL of ethanol 70% and then dried 15 minutes 
at Rt. The RNA pellet was re-suspended in 50 μL ribonuclease-free water. 
In order to eliminate any trace of DNA, RNA was treated with RQ1 RNase-
Free DNase kit (Promega, USA). Briefly, the 50 μL of RNA were incubated for 40 
minutes at 37°C with a mix of: 6 μL of 10X RQ1 DNase Buffer, 3 μL of RQ1 RNase-
Free DNase and 2 μL RNasin® Plus RNase Inhibitor (Promega, USA). After the 
DNAse treatment the RNA was cleaned up by using the Pure Link RNA mini kit 
(Ambion), according to manufacturer’s recommendation. All RNA samples were 
eluted in a final volume of 30 μL of RNase-Free water and stored at -20°C. 
 
3.2.2 RNA quantification 
 
RNA samples were quantified by using a NanoDrop 2000 spectrophotometer 
(Thermo Scientific) according to manufacturer’s recommendations.  
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3.2.3 cDNA synthesis 
 
Complementary DNA (cDNA) was synthesized using the High Capacity 
cDNA Reverse Transcription Kit (Applied BioSystems, California, USA). cDNA 
synthesis was performed in duplicate: +RT reaction with Retro Transcriptase enzyme 
(RT) and a –RT-negative control reaction with no enzyme (Figure 17).  
 
Figure 17: RT-PCR samples preparation. 
 
The cDNA reaction volume is of 20 μL and it is made up by 1ug RNA in 10 μL of 
Nuclease-free H2O plus 10 μL of master mix +RT or -RT: 
Master mix +RT for 1 sample 
Components Volume μL 
10X RT Buffer 2.0 
25X dNTP mix (100nM) 0.8 
10X RT Random Primers 2.0 
Reverse Transcriptase 1.0 
Nuclease-free H2O 4.2 
 
                  Table 1: Master Mix for cDNA synthesis. 
 
Master mix -RT for 1 sample 
Components Volume μL 
10X RT Buffer 2.0 
25X dNTP mix (100nM) 0.8 
10X RT Random Primers 2.0 
- - 
Nuclease-free H2O 5.2 
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The cDNA synthesis reaction was performed using MJ Research PTC-200 PCR 
Thermal Cycler following these thermal conditions: 
 
 Step1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 min 120 min 5 min ∞ 
 
                           Table 2: Reverse transcription cycling program. 
 
After the cDNA synthesis reaction 80 μL of Nuclease-free H2O was added to 
each samples. The cDNA products were stored at -20°C for future uses. 
 
3.2.4 Reverse Transcriptase PCR  
 
Syber Green  
Real-time PCR was performed using the Applied Biosystems StepONE Plus 
PCR machine and SYBR® Select Master Mix (Applied BioSystems, California, 
USA). For one single reaction were used 5 μL of 2X SYBR® Select Master Mix, 4 
μL of cDNA and 1 μL of Primer Mix 1:1 ratio. The primers stock concentration was 
25 μM.  
All primers were ordered from Invitrogen™ Custom DNA Oligos service. 
They were designed using the bioinformatics tool Primer3 (http://frodo.wi.mit.edu). 
 
Name Orientation Sequence 5’-3’ 
CD46 F GTCCAGTGCCTCAGGTCCTA 
CD46 R TGACCCAAACATCCAAACTG 
CD46P1 F GGACCAGATCCATTTTCACTT 
CD46P1 R ACATACACCTGCTTTATTTG 
Tubulin F CAGTTTGTGGATTGGTGCCC 
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Tubulin R CAATGGCCGTGGTGTTGC 
Murine BRAF F GGCCTATGAAGAGTACAC 
Murine BRAF R GGAGGATGTAACGGTGTCC 
Murine BRAFps F TGGCCAACCAGACCTGTCCTCA 
Murine BRAFps R GTTGACCCTCCATCACCACAAATT 
Murine β-Actin F CGTCGACAACGGCTCCGGCA 
Murine β-Actin R TGGGCCTCGTCACCCACATAGG 
 
                     Table 3: Primers sequences for RT-PCR. 
 
The following thermal conditions were used (Figure 18): 
 
 
Figure 18: Syber Green RT-PCR program. 
 
Each sample reaction was performed in triplicates. 
  
 TaqMan Probe  
Real-time PCR with TaqMan Probe was performed using the Applied 
Biosystems StepONE Plus PCR machine and TaqMan® Fast Universal PCR Master 
Mix (Applied BioSystems, California, USA). For one single reaction were used 5 μL 
of 2 X TaqMan® Fast Universal PCR Master Mix, 4.5 μL of cDNA and 0.5 μL of 
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TaqMan Probe.The TaqMan probes were ordered from Invitrogen™ Custom DNA 
Oligos service. The TaqMan MGB probes were customized with FAM at 5’ as 
reporter dye and NFQ at 3’ as non-fluorescent quencher.  
The following thermal conditions were used (Figure 19): 
 
 
                       Figure 19: TaqMan RT-PCR program. 
 
Each sample reaction was performed in triplicates. 
 
3.2.5 Data Analysis 
 
Excel and StepOne Software were used for graphing, correlation and 
statistical analyses. Data were analyzed using unpaired Student’s t test and Mantel-
Cox test. Values of p < 0.05 were considered statistically significant. The mean ± 
standard deviation of three or more independent experiments performed in triplicates 
is reported. 
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3.3 DNA 
 
3.3.1 DNA isolation 
 
After processing of TRIzol preparations for the extraction of RNA (see 2.1) 
the remaining interphase and organic phase were stored at 4°C until DNA extraction. 
In order to extract DNA 300 µL of 100% EtOH was added to each tube and mixed 
for inversion several times at Rt. After 3 minutes the samples were spun at 5,000 x g 
for 5 min at + 4°C. The supernatants containing the proteins fractions were removed 
carefully and the DNA pellets were washed with 500 µL of sodium citrate/ ethanol 
solution (0.1 M sodium citrate in 10% ethanol, pH 8.5). The samples were left to rest 
for 30 min at Rt. The samples were centrifuged at 2,000 x g for 5 min a +4°C and the 
supernatants were removed gently. To each DNA pellet was added 1.5 mL of 75% 
EtOH. After 20 min of incubation the samples were centrifuged at 12,000 x g for 5 
min. The supernatant of each sample was removed and the DNA pellets were dried at 
Rt for 10 min. The DNA pellets were resuspended in 500 µL of Nuclease-free water. 
The samples were stored at -20°C. 
 
3.3.2 DNA quantification 
 
DNA samples were quantified by using a NanoDrop 2000 spectrophotometer 
(Thermo Scientific) according to manufacturer’s recommendations.  
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3.4  Cloning  
3.4.1 General Conditions 
 
The bacteria used for transformation reaction were One Shot® Chemically 
Competent E. coli (Invitrogen, CA, USA). Each bacteria vial was left to thaw on ice 
for 10 minutes. To each vial were added 2 µL -3 µL of ligation reaction and mixed 
gently. A negative control of ligation reaction was always set up. The bacteria were 
left to rest for 5 minutes on ice and then were heat-shocked for 30 seconds at 42°C 
without shaking. After the heat-shock the bacteria were immediately transferred to 
ice. 250 µL of room temperature SOC medium was added to each bacteria vial and 
let shake (300 rpm) at 37°C for 1 hour. The bacteria were spun for 1 minute at 4000 
rpm and the pellet was dissolved in 200 µL of SOC medium. The bacteria were 
spread on pre-warmed LB- kanamycin or ampicillin selective plates and incubated 
overnight at 37°C. The day after, the positive colonies were picked and prepared for 
an overnight pre-culture with 2 ml of LB-Broth medium with antibiotics. The day 
after, 1 ml of each pre-culture was collected for DNA isolation using Plasmid Mini 
Purification kit (QIAGEN). The plasmid positivity was firstly controlled by 
restriction digestion to identify positive clones. Only the positive pre-cultures were 
prepared for an overnight culture with 250 ml of LB-Broth medium with antibiotics. 
The plasmid purifications were performed using the standard protocol of the Plasmid 
Midi Purification kit (QIAGEN). The plasmid sequences were controlled by Sanger 
sequencing using the GENEWIZ, Inc. - DNA Sequencing Services (Cambridge, MA, 
USA). 
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3.4.2 Cloning CD46 and CD46P1  
 
In order to clone the exon 5 of CD46 gene and CD46P1 pseudogene into 
TOPO pcDNA 3.1 expression vector each sequence was amplified by using 
Phusion® High-Fidelity DNA Polymerase (ThermoScientific). The following 
protocol was used: 
 
 
   
  Table 4: PCR mix and Thermal Cycler program for CD46 and CD46P1 PCR. 
 
According to the Invitrogen's TOPO TA Cloning System kit instructions 2 µL 
of fresh PCR product was used for the ligation mix into TOPO-Cloning Vector. The 
reaction was performed at Rt for 5 minutes then the reaction was placed on ice.  
2 µL of the TOPO Cloning reaction was added into a vial of One Shot® 
Chemically Competent E. coli (Invitrogen) and mixed gently. The mix was incubated 
on ice for 10 minutes before the cells were heat-shocked for 30 seconds at 42°C 
without shaking. The cells were then immediately transferred to ice. 250 µL of room 
temperature SOC medium was added to each bacteria vial and let shake (300 rpm) at 
PCR Mix 
Components Volume μL 
Phusion Polymerase 0.2 
Primer F 1 
Primer R 1 
25X dNTP mix 
(100nM) 
0.4 
DMSO 0.6 
5X HF buffer 4 
Nuclease-free H2O 12.8 
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37°C for 1 hour. 10 µL from each transformation was spread on a pre-warmed 
kanamycin selective plate and incubate overnight at 37°C.  
 
3.4.3 Human and mouse BRAFps cloning   
 
Mouse BRAFps was cloned into pCCL.sin.PPT.hPGK.GFP.Wpre kindly 
given by L. Naldini from San Raffaele-Telethon Institute for Gene Therapy, Milano, 
Italy. The same sequence has been cloned into pcDNA3-neo vector obtained by 
Invitrogen. Human BRAF pseudogene was cloned into pLenti-CMV-GFP-Puro 
(Addgene 25873).  
 
 
3.5 Transfection  
 
Plasmid transfection, cells were seeded in 12-well dishes at a density of 
120,000 cells per well. Transfection was performed 24 hours later with 
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
recommendations. Cell Medium was changed after 4 hours of transfection. Cells 
were trypsinized and seeded for the various assays 8 hours post-transfection. 
. 
3.6 Protein extraction and western blot analysis 
 
For protein extraction cells were washed twice with cold PBS then scraped 
into 500 μL of PBS and centrifuged at 13.000 rpm for 5 minutes at 4°C. The PBS 
was removed and the cell pellets were lysed with 100 μL of 1X RIPA lysis buffer 
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containing 1X HALT protease and phosphatase inhibitors on ice for 10 minutes. The 
lysates were centrifuged at 13.000 rpm for 5 minutes at 4°C. The supernatant was 
collected and store at-20°C for future uses. 
For western blot analysis, 5-20 μg of total protein was size-fractionated by 
SDS–PAGE on 4–12% Bis-Tris acrylamide NuPAGE gels in MOPS-SDS running 
buffer (Invitrogen). The proteins were transferred to nitrocellulose membranes 
(Whatman) in NuPage transfer buffer (Invitrogen) containing 10% methanol. The 
membranes were then probed with specific primary antibodies. HSP90 (610419, 
BD), BRAF (sc5284, Santa Cruz) pERK (9101, Cell Signaling) and tERK (9102, 
Cell Signaling). Secondary HRP-tagged antibodies and ECL detection reagent were 
from Amersham. 
 
 
3.7 Proliferation Assay 
 
The proliferation assays were performed by seeding 3 separate 12-well plates 
at a final density of 20x 104 cells for well. Starting from the following day (d0), one 
plate per day was washed once with PBS, fixed in 4% paraformaldehyde for 10 min 
at room temperature. Cells were washed one time with PBS and then kept in PBS at 
4°C. On the last day, all the well cells were stained with crystal violet solution (0.5% 
crystal violet in 20% methanol) for 10 min. Unbound crystal violet was removed by 
rinsing with distilled water, and cells were subsequently air dried. Next, crystal violet 
was extracted from cells with 500 μL of 10% acetic acid solution. 100 μL of crystal 
violet-acetic acid solution was used for absorbance measurement with the GloMax®-
Multi Detection System - Promega at optical density (OD) of 595 nm.  
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 3.8 microRNA prediction 
  
MicroRNA target prediction was performed using TargetScan release 6.2 
(June 2012). The tools if freely available on the web at the following web-address: 
http://www.targetscan.org/vert_61/docs/help.html 
 
 
3.9 Flow Cytometry 
        
3.9.1 BD Lyoplate 
 
V-CaP cell line was characterized by using a panel of 242 purified 
monoclonal antibodies (BD Lyoplate™ Human Cell Surface Marker Screening 
Panel). According to the manufacture instructions the lyophilized antibodies of the 
kit were reconstituted by adding 110 µL of 1X sterile PBS to each well of 
96well/plates.  The reconstituted antibodies were stored at 4ºC and used for 
screening within 10 days. Each antibody was incubated with 1 × 105 V-CaP 
according the kit guidelines. Data acquisition (10,000 gated events) was performed 
using a Cytomics FC 500 flow cytometer (Beckman Coulter) after performing an 
instrument quality control procedure. Experimental panels and data analyses were 
performed using the Kaluza (Beckman Coulter) and BD FACSDiva (Becton 
Dickinson) 
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3.9.2 Cell line flow cytometry 
 
 Adherent cells lines were trypsined and centrifuged at 1200 rpm for 4 
minutes. Then the cell pellet was washed with 1 ml of FACS Flow solution. Then 2 × 
105 cells were incubated at 4°C for 30 min with the appropriate amount of MoAbs, 
following the manufacturer's instructions. The Becton Dickinson (BD) MoAbs used 
are: CD46-FITC (cat.n.555949), CD35-FITC (cat.n.555452), CD55-PE (cat.n 
555694), CD59-PE (cat.n 555764), CD49f-PE (cat.n.555736). CD44-PE-Cy7 was 
purchased by eBioscience (cat.n. 25-0441-82). 
The cell staining was analysed using an unmodified BD FACSCantoII flow 
cytometer (BD) and compensation was set in FACS-DiVa (BD) software. 
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4. RESULTS 
 
 4.1 High-throughput screening of the prostate cancer cell line V-CaP by flow 
cytometry  
  
Prostate cancer (CaP) is the most frequently diagnosed cancer in men. 
Progression of CaP from primary to metastatic disease is associated with several 
molecular and genetic changes that can affect the expression of specific tumor-
associated antigens (TAAs) or receptors on the cells surface.   
In order to investigate the complete cell surface pattern of a prostate cancer 
cell line I used an innovative high-throughput screening flow cytometry approach. 
The aim of this experiment was to know exactly which antigens were expressed or 
not and identify new antigens subsets useful for a better characterization of prostate 
cancer cells.  The cell line chose to be screened was the V-CaP cell line which is an 
example of prostate metastatic cell line. 
The V-CaP cell line was tested with a panel of 242 different purified 
monoclonal antibodies of the BD Lyoplate screening panel. As negative control 
unstained cell samples were used. In this way it has been possible to determine the 
level of background due to cellular autofluorescence.  
The unstained cells were first gated on physical parameters (FSC and SSC) to 
exclude the majority of debris and dead cells. Afterwards, an APC vs FITC-empty 
channel dot plot was used to gate the positive cells. The last gate created was used to 
analyze all 242 .fcs files (Figure 20). 
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Figure 20: Gating strategy BD Lyoplate .fcs files: A) Gate to detect positive 
cells on APC vs FITC channel dot plot. B),C),D) Examples of gating strategy applied 
to stained cells samples. 
  
After the complete analysis of all the data, V-CaP cell line shows a variable 
positivity for 51 of totally cluster differentiation molecules (CDs) tested. In 
particular, V-CaP cells are positive (> 90%) for CD9, CD24, CD29, CD44, CD46, 
CD47, CD49a, CD49b, CD49c, CD49f, CD57, CD58, CD59, CD71, CD81, CD95, 
CD98, CD99, CD147, CD151, CD321 and CD326. The CD26, CD44, CD55, CD63, 
CD97, CD138, CD146, CD164, CD201, CD221 positivity was in the 50-90% range 
and reactivity for CD49e, CD54, CD56, CD105, CD142, CD165, CD166, CD340, 
EGF-R (Epidermal Growth Factor Receptor), Hem Progenitor Cell and HLA A,B,C 
was comprised between 10-50%. Finally, it has found a small proportion of cells (< 
10%) reactive for CD10, CD99R, CD100, CD171, CD227, CD243, SSEA-4 (Figure 
21). 
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Figure 21: Graphical representation of cluster differentiation markers on V-CaP 
cell line after the BD Lyoplate screening. 
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4.2 Membrane complement regulatory proteins expression on prostate cancer cell 
lines 
 
Thanks to the results obtained by the BD Lyoplate screening, I focused my 
attention on the study of mCRPs (CD46, CD55 and CD59). I wanted to test, with use 
of flow cytometry, the mCRPs expression pattern of other prostate cancer cell lines: 
22Rv1, PC-3, Du-145 and LNCaP. 
For this experiment, I designed a specific multicolor antibody panel (Table 
5). 
 
 
 
 
 
    .                     Table 5: Multicolor flow cytometry panel for mCRPs. 
 
 2 × 105 cells of each cell lines were incubated at 4°C for 30 min with the 
appropriate amount of MoAbs according the manufacture recommendation. For all 
staining the appropriate isotype controls and negative controls were set up. The .fcs 
files were analyzed by using BD FACSDiva Software. 
The 22Rv1, PC-3, Du-145 cell lines showed positivity for CD46  > 90% as 
previously observed with the V-CaP cell line. The LNCaP, instead, has positivity for 
CD46 of only 50%. The 22Rv1, PC-3, Du-145 CD46+ cells are also positive for 
CD44, CD49f, CD55 and CD59. The intensity of CD59 is not as high as it is the 
 Tube 1 Tube 2 Tube3 
FITC CD46 CD35 CD46 
PE CD55 CD59 CD49f 
PE-Cy7 CD44 CD44 CD44 
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CD55. All four cell lines studied are negative for CD35 expression. The LNCaP cell 
lines has a very low expression of CD44 less than <30% (Figure 22).  
 
 
 
Figure 22: Flow cytometry dot plots mCRPs molecules. 
 
 
 
 
 
4.3 CD46 psuedogene expression in prostate cancer cell lines 
 
In order to determine the expression level of CD46P1 pseudogene in prostate 
cancer cells a quantitative RT-PCR (qRT-PCR) was performed. 
RNA was isolated from 4 different prostate cancer cell lines: V-CaP, LNCaP, PC-3 
and 22Rv1. Primers were specific designed to target exon 5 in CD46P1ps in a high 
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mismatch region when aligned with CD46 sequence. Primer specificity for 
CD46P1ps was tested by using two plasmid carrying the exon 5 region specific for 
CD46 and the pseudogene. For all qRT-PCRs tubulin was used as internal control. 
As expected CD46 transcript is highly expressed in all cell lines analyzed. 
These results are in accordance with the results obtained by flow cytometry. 
Regarding the pseudogene levels, they are not detectable in PC-3, LNCaP and V-
CaP. Basal expression of CD46P1 pseudogene can be detected in 22Rv1 cell line 
(Figure 23). 
 
 
          Figure 23: qRT-PCR CD46 and CD46P1 in prostate cancer cell lines 
 
 
4.4 CD46 psuedogene expression in lymphoma cell lines 
 
In order to investigate if CD46 pseudogene could be expressed in other tumor 
cell lines we tested the lymphoma cell lines: Ly8, Val, RCK-8, Ly3. 
As for the prostate cancer cell lines qRT-PCR was performed using Syber 
Green detection method and tubulin as internal loading control. 
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In all four lymphoma cell lines CD46 gene is expressed. The levels of 
expression are similar between Ly8, Val and Ly3 with an increase in RCK-8 cell 
line. RCK-8 cell line is also the only one expressing the CD46ps. In the other three 
cell lines CD46ps is either very low or undetectable (Figure 24).  
 
 
 
           
               Figure 24: qRT-PCR CD46 and CD46P1 in lymphoma cell lines. 
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4.5 B-RAFps overexpression in mouse and human cell lines 
 
 
Due to the high homology between B-RAF gene and B-RAF pseudogene (B-
RAFps) in mice and human we hypothesized that overexpression of the non-coding 
transcript B-RAFps (in mouse and human) is able to antagonize multiple shared 
miRNAs, thus relieving translational inhibition of the mRNAs of B-RAF coding 
gene. 
In order to study the sponging effect of B-Rafps versus B-Raf gene, we 
cloned the murine full length B-Rafps into pCCL.sin.PPT.hPGK.GFP.Wpre 
expression vector.  
 
 
                  
               Figure 25: Mouse B-Rafps construct expression vector.  
 
 The mouse NIH3T3 cell line was stably transfected with the B-Rafps-
pCCL.sin.PPT.hPGK.GFP.Wpre vector and a control NIH3T3 cell line was 
established with a stable transfection of an empty-pCCL.sin.PPT.hPGK.GFP.Wpre 
vector. Stable clones of both cell lines (B-Rafps and empty) were expanded and 
tested by western blotting and proliferation assay.  
NIH3T3 cells showed up-regulated B-Raf and pERK expression compared 
with empty vector–transfected NIH3T3 cells (Figure 26-A) and also an increase in 
proliferation rate (Figure 26-B). 
 62 
 
 
 
Figure 26: A) Western Blot B) proliferation assay of NIH3T3 fibroblasts 
overexpressing B-Rafps.  
 
The same approaches have been used to study of B-RAFps sponging effect in 
human derived cell lines: PC-9 (lung). The human full length B-RAFps has been 
cloned into a pLenti-CMV-GFP-Puro expression plasmid (Figure 27). 
 
 
 
                       Figure 27: Human B-RAFps cloning construct.  
 
Control PC-9 cells were also setup with empty- pLenti-CMV-GFP-Puro vector. All 
the clones have been selected with puromycin (1µg/ml) and the tested for western 
blot and proliferation assay.  
As observed in the murine cell line system in presence of B-RAFps 
overespression there is an increase in B-RAF protein levels, which is followed by the 
increase of pERK levels (Figure 28-A). In addition to these also the PC-9-B-RAFps-
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vector cells show an increase in proliferation rate when compared to PC-9-empty-
vector (Figure 28-B).    
 
 
 
Figure 28: A) Western Blot B) proliferation assay of PC-9 cell line overexpressing 
B-RAFps.  
 
 
 
 
 
4.6 B-RAFps sponging effect is Dicer/miRNA dependent 
 
To investigate the role for Dicer-controlled miRNAs mediated cross-talk 
between B-RAF transcript and its pseudogene we utilized cell lines engineered to 
lack functional Dicer1, a ribonuclease that mediates critical step during miRNA 
biogenesis. The lack of Dicer causes a drastic reduction of mature miRNA levels. 
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The cell lines used are murine sarcoma cell line KPCD Dicerfl/Δ and KPCD 
DicerΔ/Δ (101) and human HCT-116 colon cancer cell line Dicerwt and HCT-116 
Dicermut (102). These cell lines have been transfected specifically with murine or 
human B-RAF pseudogene as in paragraph 4.4.  
Ectopic overexpression B-RAFps in HCT-116 Dicerwt and KPCD Dicerfl/Δ 
induced an increase in B-RAF expression as shown by western blots. When B-
RAFps is overexpressed in HCT-116 Dicermut or KPCD DicerΔ/Δ I did not observe an 
increase in B-RAF levels (Figure 29 A-B). These data indicate that mature miRNAs 
are critical for the crosstalk. 
 
 
           Figure 29: Western blot A) HCT-116 B) KPCD overexpressing B-RAFps. 
 
 
The increased level of B-RAF protein in HCT-116 Dicerwt and KPCD Dicerfl/Δ 
was confirmed by proliferation assays (Figure 30). The proliferation rate of the cell 
lines containing a functional Dicer in homozygosis or heterozygosis proliferate more 
than the ones without. 
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Figure 30: Proliferation assay A) HCT-116 B) KPCD overexpressing B-RAFps. 
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4.7 B-RAFps sponging effect is B-RAF dependent 
 
Mouse B-Raffl/fl fibroblasts were used in order to determine if the B-Rafps 
sponging effect is B-Raf dependent. These B-Raffl/fl fibroblasts were derived from a 
conditional knockout mouse for B-Raf gene. When the cells are infected with an 
adenovirus carrying the Cre-recombinase the B-Raf gene is genetically deleted 
because it is flanked by two loxP sites as shown in Figure 31. ` 
 
 
 
 
Figure 31: Conditional B-Raf knock-out fibroblasts.  
 
The B-Raffl/fl fibroblasts were transfected with an expression vector to 
overexpress B-Rafps and an empty-vector as negative control. The same cells were 
then infected with Ad-Cre, to knock out B-Raf gene and a negative control infection 
virus (Ad-Mock). 
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The cells infected with Ad-Mock virus do not lose B-Raf gene. When the cells are 
infected with Ad-Cre virus the B-Raf gene is genetically deleted and no B-Raf 
protein is detectable with western blot. In addition to these, B-Raffl/fl fibroblasts 
transfected with B-Rafps vector show an increase in B-Raf protein levels when 
compared to the fibroblasts transfected with the empty-vector. Increases of pERK 
levels follow the B-Raf protein increase (Figure 32). These dynamics are not 
observed in the same cells infected with Ad-Cre virus where B-Raf gene is deleted. 
In absence of B-Raf gene no mRNA transcript is produced. In this way, no cross-talk 
there is between the B-Raf gene transcript and its pseudogene. 
 
 
Figure 32: Western blot B-Raffl/fl fibroblasts overexpressing B-Rafps 
in presence or absence of Adeno-Cre infection. 
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5.  DISCUSSION 
 
5.1 CD46 and its pseudogene CD46P1 in prostate cancer  
Prostate cancer is an important disease in the modern era, based on its 
prevalence, the controversies surrounding diagnosis and treatment selection. 
Progression of prostate cancer from primary to metastatic disease is associated with 
several molecular and genetic changes that can affect the expression of specific 
tumor-associated antigens (TAAs) or receptors on the cells surface. Understanding 
how the cancer cells differ from the normal cells, might allow them to be targeted 
selectively and eliminated, thus improving therapeutic outcome. 
 The first aim of this thesis was to determinate the complete 
immunophenotype of a metastatic prostate cancer cell line (V-CaP) in order to 
identify specific sets of antigens that could better characterize the prostate cancer 
cells and they could be specifically associated with a prostate cancer stage.  
In order to this, the Vertebral-Cancer of the Prostate (V-CaP) cell line was screened 
for 242 cell surface molecules by using a high-throughput flow cytometry approach: 
the BD Lyoplate screening panel. This approach has been considered the most 
suitable technique for this screening because it provides the possibility to acquire 
data from multiple assays in a single experiment reducing the intra-lab variability 
and it is the most completed kit for human cell surface antigens screening available 
on market.  
After the analysis of all 242 .fcs files, it emerged that the V-CaP cell line has 
a variable positivity for 51 of totally cluster differentiation molecules (CDs) tested 
(Figure 21). As expected the V-CaP cell line is negative for hematological cell-
lineage specific antigens (i.e. CD3, CD4, CD8, CD34…) while it is positive for 
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molecules involved in cell adhesion such as integrins (i.e. CD49a,b,c,f).  
Interestingly, the V-CaP cell line shows, also, a high positivity for membrane 
complement regulatory proteins (mCRPs) expression: CD46, CD55, and CD59.  
The mCRPs are known for their role in the immune evasion strategy of 
tumors cells by inhibiting complement cascade activation. An overexpression of 
these molecules on cancer cells significantly limit the anti-tumor mAb therapeutic 
efficacy and increase the tumor cell metastatic potential.  
Because of that, I wanted to test other prostate cancer cell lines (22Rv1, PC-3, 
Du-145 and LNCaP) for the mCRPs expression by using a specific multicolor 
antibody panel shown in Table 5.  In addition to the mCRPs molecules, I 
investigated the expression of other membrane cell surface proteins such as CD35, 
CD44 and CD49f, due to their role in cell homeostasis. In particular, CD35 was 
interesting to study because it is an N-glycosylated member of the RCA (regulators 
of complement activation) family of proteins. As CD46 and CD46P1 genes, its 
genomic locus is in the RCA gene cluster on chromosome 1. CD35’s main function 
is to protect cells from complement-mediated lysis by serving as a cofactor for Factor 
I and inhibiting the C3 and C5 convertases. The CD44 antigen is a cell-surface 
glycoprotein involved in cell–cell interactions, cell adhesion and migration. CD44 
together with CD49f (commonly expressed on human prostate basal cells) are 
reported to be used as cell surface markers to isolate breast and prostate cancer stem 
cells (99, 100). 
Three of the cell line tested (22Rv1, PC-3 and Du-145) showed positivity for 
CD46 > 90% as previously observed in the V-CaP cell line. The LNCaP cell line, 
instead, has positivity for CD46 of only 50%. The 22Rv1, PC-3 and Du-145 CD46+ 
cells are also positive for CD44, CD49f, CD55 and CD59. The intensity of CD59 is 
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not as high as it is the CD55 one. All four cell lines (22Rv1, PC-3, Du-145 and 
LNCaP) are negative for CD35 expression (Figure 21). The CD35 negativity is not 
surprising because it is described in literature that CD35 is expressed on monocytes, 
dendritic cells and lymphocytes.   
The results obtained from the described experiments let arise other questions 
such as which mechanisms could lead to an upregulation of mCRPs expression in 
prostate cancer cell lines, in particular the upregulation of CD46 protein. 
According to me, the CD46 molecule is so interesting to be studied because: 
1- It is the highest representative molecule among the mCRPs;  
2- It is the only mCRPs molecule which has a pseudogene in human genome 
which is located in the same genomic locus of CD46 gene (RCA gene 
cluster); 
3- It is a multifunctional protein; 
4- It is used as target for prostate specific immunotherapy. 
At the time of writing this thesis, no studies have been conducted to 
investigate the role of CD46P1 as modulator molecule for CD46 gene expression 
through the ceRNA hypothesis.  As previously described in paragraph 1.1.4 a 
pseudogene may play a role as competing endogenous RNA if some conditions are 
present. First of all, it has to be transcribed. 
 For this reason, I decided to investigate if CD46P1 is transcribed in prostate 
cancer cell line by using qRT-PCR. As shown and discussed in paragraph 4.3 
CD46P1 pseudogene is expressed at low levels only in 22Rv1 cell line while in the 
other cell lines studied (V-CaP, PC-3 and LNCaP) it is undetectable.  Because of 
that, I decided to extend the CD46P1 transcript research to lymphoma cancer cell 
lines, which are an example of non-solid tumor. 
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In three lymphoma cell lines (Ly3, Ly8, Val) studied no CD46P1 transcript 
expression is undetectable. Only in one cell line, the RCK-8 it is possible to detect 
some expression of CD46 pseudogene (Figure 24).  
Why only the prostate cell line 22Rv1 and the lymphoma cell line Ly8 
express the pseudogene CD46P1 has to be investigated. It could be possible that 
these cell lines, being derived from primary tumors, could have been more exposed 
to the complement activation.  A direct consequence of that could be a transcriptional 
hyper-activation of RCA gene cluster and an increase in CD46P1 levels. 
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5.2 B-RAF as competing endogenous RNA  
 
This PhD work focused its attention on the study of B-RAF pseudogene for 
several reasons. First of all, some scientific research report that B-RAF pseudogene 
is overexpressed in human thyroid cancer (104) and other cancer types (65), 
suggesting that its deregulation may promote cancer development. Secondly, the 
MAPK pathway is commonly hyperactivated in cancer and a potential ceRNA 
activity of B-RAFps toward B-RAF may impact this signaling pathway. Finally, it is 
well known that some human hematopoietic malignancies are associated with 
overdosage of the X chromosome, which is where the B-RAF pseudogene is located.  
In this thesis it has been demonstrated that B-RAF pseudogene elicits its 
oncogenic function by decoying miRNAs from its parental gene B-RAF through a 
series of in vitro experiments.  
Murine and human B-RAF corresponding pseudogenes have been cloned in 
two expression vectors and transfected in two cell lines: PC-9 for human B-RAFps 
and NIH3T3 cell line for murine B-Rafps. According to the ceRNA hypothesis, if a 
RNA transcript with ceRNA potential is overexpressed in a cell, it can easily sponge 
and subsequently compete for the common miRNA pool shared with another 
transcript.  
When the human and murine B-RAF pseudogenes were overexpressed in PC-
9 and NIH3T3 respectively, we observed, by western blot, an increase in B-RAF and 
pERK protein levels (Figure 26-A and 28-A). In addition to these, when the same 
cells were used for proliferation assays I observe an increase in cells proliferation 
rate (Figure 26-B and 28-B) correlated to an activation of MAPK pathway 
suggested also by the western blot results discussed above.  
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Because of that, I investigated how many miRNA response elements (MREs) 
the B-RAF pseudogene and its coding-gene share both in human and in mice. As 
shown in Figure 10, BRAFps and BRAF share a large number of common MREs: 
40 different MREs in human while in mice around 52. These numbers suggest that 
the two transcripts can cross-talk using common miRNAs molecules.  
The next question we wanted to answer was: if no more mature miRNAs are 
produced in the cell what happens to the cross-talk between the B-RAFps and its 
coding-gene transcript? According to the ceRNA hypothesis without miRNAs no 
cross-talk could be possible. 
In order to investigate the role for Dicer-controlled miRNAs mediated cross-
talk between B-RAF transcript and its pseudogene I utilized cell lines engineered to 
lack functional Dicer1, a ribonuclease that mediates critical step during miRNA 
biogenesis. The lack of Dicer causes a drastic reduction of mature miRNA levels. 
The cell lines used are murine sarcoma cell line KPCD Dicerfl/Δ and KPCD DicerΔ/Δ 
and human HCT-116 colon cancer cell line Dicerwt and HCT-116 Dicermut. 
 The results obtained clearly show that in absence of Dicer1, no mature 
miRNAs are generated and B-RAF gene transcript and it pseudogene cannot 
crosstalk. In fact, when we compare the B-RAF protein level in HCT-116 Dicerwt 
and HCT-116 Dicermut cells overexpressiong the pseudogene, we observed that B-
RAF protein level increase only in the cell line with a functional Dicer (HCT-116 
Dicerwt ) (Figure 29-A).  
The next point I wanted to investigate was to understand if the sponging 
effect of B-RAF pseudogene is B-RAF dependent. In order to do that, I used a mouse 
B-Raffl/fl fibroblast cell line where it was possible to delete both allele copies of B-
Raf gene after Ad-Cre virus infection (Figure 31). As shown in Figure 32  
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When the B-Rafps is overexpressed in the B-Raffl/fl fibroblast cell line infected with 
the control virus (Ad-Mock), unable to induce the genetic B-Raf gene deletion, the 
B-Raf protein levels increase followed by pERK increase too. When the same cell 
line is infected with Ad-Cre virus, the two copies of B-Raf gene are deleted and no 
B-Raf is detectable. What is important is that without B-Raf no increase in pERK 
protein is detectable too in response to B-Rafps overexpression. 
 This experiment supports the notion that the effect of BRAFps on MAPK 
activation is indeed mediated by B-RAF. 
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6.  FINAL OBSERVATIONS 
 
This thesis has had two protagonists: the B-RAF pseudogene and the CD46P1 
pseudogene. The in vitro experiments conducted on B-RAF pseudogene, clearly 
show that it is a pseudogene that functions as ceRNA and promotes oncogenesis 
when deregulated. The in vitro results also give confirmation to what observed in 
vivo by Karreth et al. (103). 
At this point it is not possible to define CD46P1 as a pseudogene with ceRNA 
ability. The data obtained are preliminary and many other in vitro experiments need 
to be done. Nevertheless, CD46 and its CD46P1 revealed to be interesting molecules 
to be studied.   
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